In an effort to reduce the incidence and severity of acute GVHD (aGVHD), we have developed a new prophylaxis regimen combining cyclosporine and MTX with a short 30-day course of low-dose (500 mg per day) mycophenolate mofetil. This regimen was studied prospectively 100 patients undergoing HLA-matched and 1-antigen-mismatched allogeneic peripheral blood SCT from related donors. The cumulative incidence of aGVHD was 16% (grades II-IV (9.5%) and grades III-IV (1%)). The cumulative incidence of chronic GVHD (cGVHD) was 53% with 28% extensive cGVHD. The cumulative incidence of transplant-related mortality at 100 days and 3 years were 6 and 13%. The estimated probabilities of disease-free survival at 3 years in standard-and high-risk patients were 77 and 30%, respectively (Po0.0001). The estimated probabilities of overall survival at 3 years in standard-and high-risk patients were 77 and 37%, respectively (Po0.0001). These data show a substantial decrease in the risk of developing aGVHD without an increase in relapse or any adverse impact on survival in standard-risk patients.
Introduction
For decades, cyclosporine (CsA) combined with short-course MTX has been considered the 'gold standard' for GVHD prophylaxis in allogeneic (allo)-BMT. In 1997, the European Group for Blood and Marrow Transplantation (EBMT) reported that 93% of BMT centers were using CsA-MTX for GVHD prophylaxis. 1 Recently, tacrolimus has been introduced as a new agent for the prophylaxis of GVHD. CsA or tacrolimus are now commonly used in combination with MTX and there is considerable debate about whether one calcineurin inhibitor is better than the other in this patient population. [2] [3] [4] Nevertheless, severe GVHD continues to be one of the major causes for morbidity and mortality following allo-hematopoietic SCT (HSCT). Anti-thymocyte/ anti-lymphocyte globulin and Campath have been demonstrated to significantly reduce the incidence of both acute GVHD (aGVHD) and chronic GVHD (cGVHD) in the related allo-transplant setting. [5] [6] [7] Unfortunately, although those measures resulted in a reduction of GVHD, they were also associated with an increased risk of leukemia relapse, severe infection and engraftment failure without demonstrating improvement in overall survival (OS). [5] [6] [7] It is felt that immunosuppression aimed to treat GVHD compromises the desirable GVL effects, thus resulting in enhanced leukemia relapse rates. Therefore, novel immunomodulatory strategies are needed to optimally balance adequate GVHD prophylaxis and maximize GVL effects to improving overall outcomes in allo-transplantation. This could be accomplished through redesign or modification of conditioning regimens, through graft engineering, or investigation of new GVHD prophylaxis regimens.
Mycophenolate mofetil (MMF) is a powerful immunosuppressive agent that inhibits de novo purine synthesis resulting in impaired proliferation of activated lymphocytes. 8 Preclinical studies of allo-HSCT in a canine model showed that MMF in combination with CsA has activity in preventing GVHD. 9 This concept has already been explored in several early clinical trials. [10] [11] [12] In those studies, typically, MMF was combined with standard agents, CsA, MTX or prednisolone. [12] [13] [14] A prospective randomized trial in a matched sibling allo-BMT setting compared CsA and MTX with CsA and MMF showed that the incidences of grades II-IV aGVHD were 48% in the MMF group and 37% in the MTX group (P ¼ 0.49). 15 Between 1998 and 2001, several studies demonstrated safety and efficacy for MMF in GVHD therapy and prophylaxis in mismatched related or unrelated allo-HSCT. [12] [13] [14] Although MMF has been recognized as being a very promising agent for GVHD prophylaxis, the optimal combination regimen utilizing existing drugs as well as determining the optimal time course and dose of MMF needs further investigation. To further refine the role of MMF, in June of 2001, we initiated a clinical phase I trial for a new GVHD prophylaxis regimen where CsA and MTX is combined with a short course (30 days) of low dose MMF at our institute. 16 Subsequently, we initiated a prospective cohort clinical trial using this regimen where the dose of MMF was set at 500 mg per day Â 30 days. A total of 100 patients were enrolled. The goal was to study the effectiveness of a combination of MMF with CsA and MTX for GVHD prophylaxis in related HLA-matched allo-HSCT and compare the results to historic controls from the literature as well as the Chinese bone marrow registry.
Patients and methods

Patients
From June 2001 to July 2007, a total of 100 patients with hematologic malignancy received related HLA-matched and single antigen-mismatched allo-peripheral blood SCT (PBSCT) at our institute. Eligible patients had to be appropriate candidates for a myeloablative allo-HSCT and were offered to participate in a prospective cohort clinical trial after signing informed consent. The aim was to investigate safety and efficacy of a new GVHD prophylaxis regimen. Prior to its implementation, the study was approved by the ethical committee of the Guangxi Medical University in compliance with the Helsinki Declaration. Patients and transplantation characteristics are summarized in Table 1 . Standard-risk patients were defined as those with AML or ALL in first CR1, CML in chronic phase (CP), or myelodysplastic syndrome (MDS) as refractory anemia (RA), or non-Hodgkin's lymphoma (NHL) in CR, or multiple myeloma (MM) in CR. High-risk patients were defined as those with AML or ALL in subsequent CR, in relapse or considered refractory to standard chemotherapy, CML in accelerated phase (AP) or in blastic phase (BC), MDS as RA with excess blasts (RAEB) or NHL currently not in CR at the time of transplant.
Conditioning regimens
Two conditioning regimens were used in this study. All patients with lymphoid malignancies (ALL, NHL and MM) received CY (60 mg/kg per day Â 2 days) and TBI (5.0 Gy per day Â 2 days) as their conditioning regimens. Patients with AML, CML and MDS received CY (60 mg/ kg per day Â 2 days) and BU (4 mg/kg per day Â 4 days) conditioning without TBI.
GVHD prophylaxis GVHD prophylaxis consisted of CsA, MTX and MMF. Intravenous CsA (3 mg/kg per day) was administered until day þ 30 and then switched to the oral route (6 mg/kg per day). Trough levels were targeted at 200-300 ng/ml until 3-6 months and dose adjustments were made accordingly. MTX was administered i.v. at doses of 15 mg/m 2 on day þ 1 and 10 mg/m 2 on days þ 3, þ 6 and þ 11. MMF was given orally at a dose of 250 mg b.i.d. from days À1 to þ 20 and tapered to a dose of 250 mg daily from days þ 21 to þ 30. No dose adjustments for MMF were made and all patients were able to take the outlined prescribed course.
Procurement of hematopoietic stem cells
We employed the concept of high dose of stem cells infusion for our treatment protocol. 17 Stem cell donors were treated with G-CSF at a dose of 5 mg/kg per day by s.c. injection from days À3 to þ 1. Mononuclear cells (MNCs) were collected by apheresis with a Spectra machine (Baxter, CS-3000 Plus, USA) on days 0 to þ 2 for three times according to standard procedures. The apheresis was stopped when the donor platelet count fell below 50 Â 10 
Supportive care
Supportive care measures were provided according to good medical practice standards. G-CSF (5 mg/kg per day s.c.) was administered to patients on day þ 1 until the ANC exceeded 1 Â 10 9 per liter. Fluconazole was given to all patients from days À5 to þ 30. Trimethoprim sulfamethoxazole was administered for prophylaxis of pneumocystis carinii infection. Acyclovir (250 mg i.v. b.i.d.) was given on days þ 1 to þ 30. Patients were monitored weekly by CMV pp65 antigenemia test and CMV-IgM test. Patients with CMV antigenemia received ganciclovir (5 mg/kg per day, i.v., Â 14 days)and i.v. immunoglobulin.
Statistical analyses
Analysis was carried out in 100 patients and includes data collected and analyzed through 31 October 2007. The median time of follow-up in surviving patients was 35 months (range, 3.5-75 months). The primary end point of this study was the cumulative incidence of aGVHD. Secondary end points included the cumulative incidence of cGVHD, transplant-related mortality (TRM), disease relapse, mortality from disease progression (MDP), OS and disease-free survival (DFS). Acute and cGVHD were graded according to published standard criteria. 18 OS was calculated from the day of transplantation to the date of last follow-up or death. DFS was counted from the day of transplantation to relapse or death. Both OS and DFS were estimated by the Kaplan-Meier method. 19 In calculating the time-to-event for analysis of incidence of aGVHD, cGVHD, TRM and MDP where competing risks alter the assessment of frequency, the cumulative incidences were estimated. 20 OS, DFS, TRM, MDP were compared between standard-risk and high-risk patients. The log rank test was used to assess the significance of differences for comparison of the two groups. All statistical analyses were performed using the statistical software program SPSS version 13.0 (SPSS, Chicago, IL, USA), with the exception of the cumulative incidence analyses, which were carried out with using the statistical software program NCSS 2007 (Number Cruncher Statistical System, Kaysville, UT, USA).
Results
Engraftment
Ninety-eight patients achieved sustained engraftment. The median number of days to reach an ANC of 0.5 Â 10 9 per liter was 12 days (range, 9-18 days). The median time to reach an unsupported platelet count of 20 Â 10 9 per liter was 18 days (range, 12-28 days). Two patients failed engraftment. One was a patient with CML, who had been treated with hydroxyurea for 3 years previously. There was no prior treatment with alkylating agents, the patient received 9.3 Â 10 6 per kg of CD34 cells and reasons for engraftment failure could not be determined. The other patient died from multiorgan failure following sepsis on day þ 12 and the neutrophil count was only 0.25 Â 10 9 per liter at the time of death.
GVHD
Of 100 patients, 84 patients experienced no aGVHD and 16 patients developed aGVHD ( Table 2 ). The cumulative incidence of aGVHD was 16.0% (95% confidence interval (CI): 10.2-25.1%). The cumulative incidence of grade I aGVHD was 9.3% (95% CI: 8.5-9.7%). The cumulative incidence of grades II-IV aGVHD was 9.5% (95% CI: 5.1-17.7%; Figure 1a ). The cumulative incidence of grades III-IV aGVHD was 1.0% (95% CI: 0.1-7.0%). The grade IV aGVHD patient, a 56-year-old patient with active ALL, was the only patient who died from aGVHD in our study. Forty-one patients developed cGVHD. TwentyThree patients developed limited cGVHD and eighteen patients developed extensive cGVHD ( Table 2 ). The cumulative incidence of cGVHD was 53.3% (95% CI: 42.8-66.3%; Figure 1b) . The cumulative incidence of extensive cGVHD was 28.2% (95% CI: 18.6-42.6%).
Transplantation-related morbidity and mortality Twelve patients died free of disease. The cumulative rate of TRM at 100 days was 6.0% (95% CI: 2.8-13.0%). The cumulative rate of TRM at 3 years in all patients was 12.6% (95% CI: 7.4-21.4%). The cumulative rates of TRM at 3 years in standard-risk and high-risk patients were 3.4% (95% CI: 0.8-13.3%) and 27.6% (95% CI: 16.2-47.1%), respectively, (Po0.001; Figure 2a ). The causes of TRM are depicted in Table 3 . Some common complications of the transplantation procedure included veno-occlusive disease (VOD; n ¼ 11; 11%), hemorrhagic cystitis (n ¼ 6; 6.0%), pure red cell aplasia (n ¼ 5; 5.0%), CMV antigenemia (n ¼ 28; 28%). Three patients developed CMV interstitial pneumonitis. Thirty patients (30%) completed 4 days of MTX. Sixty-seven patients (67%) completed 3 days and three patients (3%) only finished 2 days of the intended MTX course, as doses had to be held for mucositis. Incidence and grades of mucositis are shown in Table 4 .
Disease response and relapse
All patients with malignant diseases (n ¼ 98) who engrafted achieved a CR. Twenty-three patients (AML, n ¼ 9; ALL, n ¼ 6; CML, n ¼ 6; NHL, n ¼ 2) relapsed. Among those patients, 16 patients belonged to high-risk group and 7 patients to standard-risk group. The median time to relapse was 6 months (3-12 months). Nineteen patients died from Table 2 The incidences of acute and chronic GVHD Acute GVHD n (%) Chronic GVHD n (%) Figure 2b ). Four relapsed patients achieved another longlasting (4, 15, 40, 50 months) CR after the combination of donor lymphocyte infusion and chemotherapy or radiation therapy.
Overall survival
With a median time of follow-up for 35 months, 66 of 100 patients were alive, and 62 of those alive were without disease. The estimated probabilities of DFS and OS at 3 years were 61.6% (95% CI: 51.6-71.6%) and 65.2% (95% CI: 55.3-75.1%). The estimated probabilities of DFS at 3 years in standard-risk and high-risk patients were 76.5% (95% CI: 64.4-88.6%) and 29.6% (95% CI: 14.4-44.9%), respectively (Po0.0001; Figure 3a) . The estimated probabilities of OS at 3 years in standard-risk and high-risk patients were 77.4% (95% CI: 65.1-89.7%) and 36.5% (95% CI: 20.2-52.7%), respectively (Po0.0001; Figure 3b ). Abbreviations: MDP ¼ mortality from disease progression; TRM ¼ transplant-related mortality; VOD ¼ veno-occlusive disease.
Discussion
The primary goal of this clinical study was to determine the efficacy of a new GVHD preventive regimen in patients undergoing related matched allo-SCT. Our early clinical data supported a favorable impact of a low dose and short course of MMF added to a more standardized prophylaxis regimen. 16 aGVHD remains a major cause of morbidity and mortality in allo-HSCT. It develops in 30-60% of recipients of sibling matched allografts and mortality (direct or indirect) can be as high as 50%. 2 We conducted a literature search to compare outcomes of various studies that were conducted under similar conditions in respect of transplant indications as well as the conditioning regimens utilized. GVHD prophylaxis in most studies typically was a combination of CsA and MTX and the utilized donor graft cells were typically related matched PBSC. [21] [22] [23] [24] [25] In those historic studies, the cumulative incidences of grades II-IV and III-IV aGVHD ranged between 37.4 and 65% and 15 and 28%, respectively. Within the Chinese population, the incidences of grades II-IV aGVHD in comparable settings range between 21.6 and 40.0%. [26] [27] [28] In our study, the cumulative incidences of grades II-IV and III-IV aGVHD were substantially decreased at 9.5 and 1.0%, respectively. In our series of 100 patients, only 1 patient developed severe aGVHD.
The cumulative incidences of cGVHD and extensive cGVHD at 2-3 years in comparable historic studies were reported to range between 62.1 and 85 and 40 and 47.1%, respectively. [21] [22] [23] [24] [25] Within the Chinese population, the incidences of cGVHD ranges between 37.8 and 43.4%. [26] [27] The cumulative incidences of cGVHD and extensive cGVHD at 3 years fell to 53.3 and 28.2% in our trial.
The cumulative incidences of TRM at 100 days and at 2-3 years in comparable studies ranged between 7.4 and 15 and 21 and 30.3%, respectively. [21] [22] [23] [24] [25] The 2-3 years DFS in standard-risk and high-risk patients were reported to range between 64.7 and 65.2 and 34.9 and 40.5%, respectively. [24] [25] In our study, the cumulative rates of TRM at 100 days and at 3 years fell into 6.0 and 12.6%. The DFS at 3 years in standard-risk and high-risk patients in our study were 76.5 and 29.6%. Although cGVHD, DFS and TRM appear to be improved when compared to historic controls, the design of the study was not randomized and therefore needs to be interpreted with caution. However, a dramatic improvement was seen for the incidence of severe aGVHD. We observed a near elimination of severe aGVHD in standard-risk patients. Of note, disease relapse rates were not increased when compared to historic controls. We have not yet studied the underlying cellular mechanisms for this dramatic improvement of this regimen on GVHD although that work is in progress at our institution.
When compared to other new immunosuppressive drugs, the advantage of the MMF regimen is the relatively low incidence of adverse events. The major adverse effect is dose-dependent myelosuppression of all hematopoietic lineages. 12 However, we did not observe myelosuppression or other serious adverse effects related to MMF in our study. We attribute this lack of myelosuppression to the low dose of MMF we have used in this study. Traditionally, in GVHD combination regimens doses of 2-3 g per day of MMF have been utilized. 15, 29 Recently, Kaushik et al.
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reported a retrospective study where MMF doses of 2 g per day were compared with 1 g per day that showed a reduced side-effect profile without impaired efficacy for the lowerdose MMF. We utilized an even lower dose (500 mg per day) of MMF that was administered as a short course (30 days) and which we determined to be effective and safe in preventing severe aGVHD when given in combination with CsA and MTX in related matched allo-HSCT. Disease free survival Because GVHD and GVL effects are closely related and both are affected by immunosuppressive agents, GVHD management remains controversial. The International Blood and Marrow Transplant Research and EBMTR data suggest that the best outcome is achieved in patients who develop mild GVHD. [31] [32] Titration of GVHD without increasing morbidity and mortality remains a major challenge to transplant physicians. Excessive immunosuppression for the purpose of GVHD prophylaxis might reduce the incidences of severe GVHD, but in turn is associated with an increased risk of leukemia relapse, severe infection and engraftment failure. Our study provides evidence that MMF can be effectively administered at lower doses over a shorter interval, which may help avoiding excessive immunosuppression. Other potential factors that might have led to somewhat more favorable outcomes in our study when compared to historical controls were the accrual of younger patients with CML in CP. We also employed both high-dose stem cell infusion as well as PBSC-derived grafts for our study that may have resulted in better outcomes. [33] [34] [35] [36] [37] [38] Although in our study, the incidence of aGVHD was low, the incidence of cGVHD remained relatively high, nevertheless, it stayed within the range of historical controls. Furthermore, neither aGVHD nor cGVHD was statistically significantly associated with the CD34 cells doses infused in our study (P40.05). The incidence and severity of aGVHD has been reported to be similar with PBSCT and BMT, yet PBSCT has been associated with more cGVHD. [39] [40] The high incidence of cGVHD could be explained with our use of PBSCT and also due to the fact that MMF was only given for 30 days. Additional studies using the low-dose regimen over extended periods to study the impact on cGVHD are warranted.
Our results suggest that the combination of CsA, MTX, low dose and short course of MMF in related HLAmatched and single antigen-mismatched allo-PBSCT can effectively decrease the risk for aGVHD without adversely impacting other outcomes such as survival and disease relapse in standard-risk patients. It clearly remains a challenge of the future to improve the outcomes for those patients with high-risk features. Although the study is limited by being a single institution nonrandomized prospective cohort clinical trial, the data are encouraging to justify implementation of a larger multicenter randomized study.
